278 related articles for article (PubMed ID: 20804567)
41. Cooperative effect of hepatocyte growth factor and fibronectin in anchorage-independent survival of mammary carcinoma cells: requirement for phosphatidylinositol 3-kinase activity.
Qiao H; Saulnier R; Patryzkat A; Rahimi N; Raptis L; Rossiter J; Tremblay E; Elliott B
Cell Growth Differ; 2000 Feb; 11(2):123-33. PubMed ID: 10714768
[TBL] [Abstract][Full Text] [Related]
42. FOXC1 identifies basal-like breast cancer in a hereditary breast cancer cohort.
Johnson J; Choi M; Dadmanesh F; Han B; Qu Y; Yu-Rice Y; Zhang X; Bagaria S; Taylor C; Giuliano AE; Amersi F; Cui X
Oncotarget; 2016 Nov; 7(46):75729-75738. PubMed ID: 27708239
[TBL] [Abstract][Full Text] [Related]
43. Basal-like subtype of breast cancer: a review of its unique characteristics and their clinical significance.
Kobayashi S
Breast Cancer; 2008; 15(2):153-8. PubMed ID: 18311481
[TBL] [Abstract][Full Text] [Related]
44. Constitutive NOTCH3 Signaling Promotes the Growth of Basal Breast Cancers.
Choy L; Hagenbeek TJ; Solon M; French D; Finkle D; Shelton A; Venook R; Brauer MJ; Siebel CW
Cancer Res; 2017 Mar; 77(6):1439-1452. PubMed ID: 28108512
[TBL] [Abstract][Full Text] [Related]
45. Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue.
Lindemann K; Resau J; Nährig J; Kort E; Leeser B; Annecke K; Welk A; Schäfer J; Vande Woude GF; Lengyel E; Harbeck N
Histopathology; 2007 Jul; 51(1):54-62. PubMed ID: 17593080
[TBL] [Abstract][Full Text] [Related]
46. Basal breast cancer: a complex and deadly molecular subtype.
Bertucci F; Finetti P; Birnbaum D
Curr Mol Med; 2012 Jan; 12(1):96-110. PubMed ID: 22082486
[TBL] [Abstract][Full Text] [Related]
47. Deconstructing the molecular portrait of basal-like breast cancer.
Yehiely F; Moyano JV; Evans JR; Nielsen TO; Cryns VL
Trends Mol Med; 2006 Nov; 12(11):537-44. PubMed ID: 17011236
[TBL] [Abstract][Full Text] [Related]
48. In bone metastasis miR-34a-5p absence inversely correlates with Met expression, while Met oncogene is unaffected by miR-34a-5p in non-metastatic and metastatic breast carcinomas.
Maroni P; Puglisi R; Mattia G; Carè A; Matteucci E; Bendinelli P; Desiderio MA
Carcinogenesis; 2017 May; 38(5):492-503. PubMed ID: 28334277
[TBL] [Abstract][Full Text] [Related]
49. Salivary gland-like tumors of the breast express basal-type immunohistochemical markers.
Reyes C; Jorda M; Gomez-Fernández C
Appl Immunohistochem Mol Morphol; 2013 Jul; 21(4):283-6. PubMed ID: 22935826
[TBL] [Abstract][Full Text] [Related]
50. H
Chen MK; Du Y; Sun L; Hsu JL; Wang YH; Gao Y; Huang J; Hung MC
J Biol Chem; 2019 May; 294(21):8516-8528. PubMed ID: 30962283
[TBL] [Abstract][Full Text] [Related]
51. Transforming growth factor-beta signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion.
Cheng N; Chytil A; Shyr Y; Joly A; Moses HL
Mol Cancer Res; 2008 Oct; 6(10):1521-33. PubMed ID: 18922968
[TBL] [Abstract][Full Text] [Related]
52. [Roles of immunohistochemistry in prognostic assessment of basal-like breast cancer].
Liu H; Fan QH; Zhang ZH; Li X; Yu HP; Liu GZ; Meng FQ
Zhonghua Bing Li Xue Za Zhi; 2009 Jan; 38(1):23-8. PubMed ID: 19489221
[TBL] [Abstract][Full Text] [Related]
53. Low-grade and high-grade mammary carcinomas in WAP-T transgenic mice are independent entities distinguished by Met expression.
Otto B; Gruner K; Heinlein C; Wegwitz F; Nollau P; Ylstra B; Pantel K; Schumacher U; Baumbusch LO; Martin-Subero JI; Siebert R; Wagener C; Streichert T; Deppert W; Tolstonog GV
Int J Cancer; 2013 Mar; 132(6):1300-10. PubMed ID: 22907219
[TBL] [Abstract][Full Text] [Related]
54. Amplification of SOX4 promotes PI3K/Akt signaling in human breast cancer.
Mehta GA; Parker JS; Silva GO; Hoadley KA; Perou CM; Gatza ML
Breast Cancer Res Treat; 2017 Apr; 162(3):439-450. PubMed ID: 28176176
[TBL] [Abstract][Full Text] [Related]
55. Obesity-mediated regulation of HGF/c-Met is associated with reduced basal-like breast cancer latency in parous mice.
Sundaram S; Freemerman AJ; Galanko JA; McNaughton KK; Bendt KM; Darr DB; Troester MA; Makowski L
PLoS One; 2014; 9(10):e111394. PubMed ID: 25354395
[TBL] [Abstract][Full Text] [Related]
56. C1orf106, an innate immunity activator, is amplified in breast cancer and is required for basal-like/luminal progenitor fate decision.
Ma J; Liu C; Yang D; Song J; Zhang J; Wang T; Wang M; Xu W; Li X; Ding S; Zhan J; Zhang H
Sci China Life Sci; 2019 Sep; 62(9):1229-1242. PubMed ID: 31376015
[TBL] [Abstract][Full Text] [Related]
57. p53 deficiency induces cancer stem cell pool expansion in a mouse model of triple-negative breast tumors.
Chiche A; Moumen M; Romagnoli M; Petit V; Lasla H; Jézéquel P; de la Grange P; Jonkers J; Deugnier MA; Glukhova MA; Faraldo MM
Oncogene; 2017 Apr; 36(17):2355-2365. PubMed ID: 27775073
[TBL] [Abstract][Full Text] [Related]
58. Transforming growth factor alpha and mouse models of human breast cancer.
Humphreys RC; Hennighausen L
Oncogene; 2000 Feb; 19(8):1085-91. PubMed ID: 10713694
[TBL] [Abstract][Full Text] [Related]
59. Expression of the c-Met/HGF receptor in human breast carcinoma: correlation with tumor progression.
Beviglia L; Matsumoto K; Lin CS; Ziober BL; Kramer RH
Int J Cancer; 1997 Jun; 74(3):301-9. PubMed ID: 9221809
[TBL] [Abstract][Full Text] [Related]
60. The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis.
Aprelikova O; Chen K; El Touny LH; Brignatz-Guittard C; Han J; Qiu T; Yang HH; Lee MP; Zhu M; Green JE
Clin Epigenetics; 2016; 8():38. PubMed ID: 27081402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
